{Reference Type}: Case Reports
{Title}: Lenvatinib in multimodal therapy for unresectable radioactive iodine-naïve differentiated thyroid cancer: A case report with literature review.
{Author}: Kim HAJ;Nichols AC;Rachakonda R;Inculet R;Sathya J;Rachinsky I;Winquist E;
{Journal}: Cancer Rep (Hoboken)
{Volume}: 0
{Issue}: 0
{Year}: Jun 2022 17
暂无{DOI}: 10.1002/cnr2.1654
{Abstract}: <B>BACKGROUND: </B>Patients with unresectable or metastatic differentiated thyroid carcinoma (DTC) are rare and require individualized therapy. This may require approaches not typically used in resectable disease. We report a patient treated with lenvatinib and external beam radiation therapy.<BR><B>METHODS: </B>An 87-year-old woman presented with cT4N1aM1 papillary thyroid carcinoma with tracheal invasion. She was not a candidate for surgery, radioactive-iodine, or radiation, so a trial of lenvatinib was offered. Her tumor showed clinical, biochemical, and radiological response after 5 months of lenvatinib, and she subsequently received external beam radiation. She enjoys good quality of life without evidence of cancer progression off therapy 21 months post-initiation of treatment.<BR><B>CONCLUSIONS: </B>Lenvatinib may be effective in RAI-naïve advanced DTC patients as a component of individualized multimodal therapy when conventional options are not feasible.